Back to News
Nov 7, 2025 12:00 PM

Sichuan Biokin Launches Hong Kong IPO; Eyes Broader Mainland Investor Reach Via Stock Connect

Biopharmaceutical company Sichuan Biokin Pharmaceutical (2615.HK; 688506.SH) launched its Hong Kong IPO on Friday, aiming to raise up to HK$3.36 billion ($432 million) by selling 8.63 million shares for between HK$347.50 and HK$389 each. Subscriptions will close on Nov. 12, with a Hong Kong trading debut set for Nov. 17.

The company is already listed on China's domestic A-share market in Shanghai, meaning it's eligible for inclusion in the Hong Kong Stock Connect program that ...